chufangao/CTO huggingface dataset:
Clinical trial NCT03364686: Transfusion of Biotin-Labeled Red Blood Cells
Official title: Transfusion of Biotin-Labeled Red Blood Cells for the Evaluation of Genetic Factors That Contribute to Donor Differences in Red Blood Cell Storage and Post-Transfusion Red Blood Cell Recovery
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to enrollment challenges related to COVID and lack of coordinator support
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-09-16
Primary completion date: 2021-03-02
Completion date: 2021-06-29
Limitations and caveats: The clinical trial was terminated early due to challenges with enrollment and lack of study coordinator support. Early termination leading to small numbers of subjects analyzed.
Clinical trial NCT04983498: Enhanced Recovery Pathway for Endoscopy
Official title: Evaluation of an Enhanced Recovery Pathway for Endoscopy Patients Receiving Moderate Sedation
Sponsor: Northwestern University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Investigator left organization before study initiated.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-01
Primary completion date: 2021-12-01
Completion date: 2022-01-01
Plan to share individual participant data: NO
Clinical trial NCT05431907: Phase 1/2 Study Evaluating Safety and Potential Efficacy of Allocetra-OTS Via Pressurized Intra-Peritoneal Aerosol Chemotherapy as Add-on to Standard of Care Chemotherapy for Treatment of Peritoneal Metastasis
Official title: Phase 1/2 Study Evaluating Safety and Potential Efficacy of Allocetra-OTS Via Pressurized Intra-Peritoneal Aerosol Chemotherapy as Add-on to Standard of Care Chemotherapy for Treatment of Peritoneal Metastasis
Sponsor: Enlivex Therapeutics RDO Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-06-29
Primary completion date: 2024-03-14
Completion date: 2024-03-14
Plan to share individual participant data: NO
Clinical trial NCT04066244: Study of Safety and of the Mechanism of BLZ945 in ALS Patients
Official title: An Open-label, Adaptive Design Study in Patients With Amyotrophic Lateral Sclerosis (ALS) to Characterize Safety, Tolerability and Brain Microglia Response, as Measured by TSPO Binding, Following Multiple Doses of BLZ945 Using Positron Emission Tomography (PET) With the Radioligand [11C]-PBR28
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study terminated after assessment of potential benefit-risk from available data
Enrollment: 28.0 (ACTUAL)
Number of arms: 8.0
Start date: 2019-12-30
Primary completion date: 2024-02-01
Completion date: 2024-02-01
Plan to share individual participant data: UNDECIDED
IPD sharing description: Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03931785: A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome
Official title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Study of MD-7246 Administered Orally for 12 Weeks to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome
Sponsor: Ironwood Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 515.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-05-01
Primary completion date: 2020-02-26
Completion date: 2020-03-11
Baseline population: Safety Population: all participants who received at least one dose of study drug
Clinical trial NCT03400956: Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)
Official title: A Randomized, Parallel-group, Double-blind and Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Vilaprisan in Subjects With Uterine Fibroids
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Due to a change in the development program, the study was closed prematurely.
Enrollment: 103.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-01-24
Primary completion date: 2019-03-23
Completion date: 2021-06-30
Baseline population: Participants in Full analysis set (FAS) was analyzed. The FAS consisted of all randomized subjects, excluding randomized subjects who did not start treatment Period 1 (never received study drug) due to the study being temporarily paused, including 96 participants.
Limitations and caveats: * The trial was terminated earlier than planned. It was sufficiently advanced to allow for meaningful analysis.~* In many subjects, follow up phase was longer than the planned one.~* Safety evaluations were not limited to the planned timepoints.
Plan to share individual participant data: NO
IPD sharing description: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA Principles for responsible clinical trial data sharing. This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Clinical trial NCT03862053: Manuka Eye Droops for Treatment of Allergy
Official title: A Phase 4 Study to Assess the Clinical Efficacy and Safety of Manuka Eye Drops for Treatment of Allergy
Sponsor: Toyos Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: not enough time to complete trial;covid
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-01
Primary completion date: 2020-10-07
Completion date: 2020-10-07
Plan to share individual participant data: UNDECIDED
IPD sharing description: If requested, data records without identifying patient information could be shared
Clinical trial NCT03956355: Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)
Official title: A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults
Sponsor: Dermavant Sciences, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 510.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-21
Primary completion date: 2020-05-26
Completion date: 2020-05-26
Plan to share individual participant data: NO
Clinical trial NCT04055389: Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis
Official title: Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis: A Randomized, Double-blinded, Placebo - Controlled Trial (PiVoT-AC Trial)
Acronym: PiVoT
Sponsor: Milton S. Hershey Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Challenges with recruitment
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-01
Primary completion date: 2022-02-22
Completion date: 2022-02-22
Plan to share individual participant data: NO
Clinical trial NCT03770403: A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.
Official title: A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness
Acronym: ADAPT+
Sponsor: argenx (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 151.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-03-01
Primary completion date: 2022-06-23
Completion date: 2022-06-30
Baseline population: The Safety Analysis set consisted of all participants who rolled over from ARGX-113-1704 and received \>=1 dose or part of a dose of efgartigimod in this study.
Plan to share individual participant data: NO
Clinical trial NCT03381729: Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy
Official title: Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Acronym: STRONG
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Based upon overall strategic objectives within the broader intrathecal clinical development program, Novartis Gene Therapies decided to terminate the study early.
Enrollment: 32.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-12-14
Primary completion date: 2021-11-18
Completion date: 2021-11-18
Baseline population: Safety Analysis Set: All participants given an AVXS-101 intrathecal injection. Participants were analyzed according to actual dose received.
Limitations and caveats: A comparison of the results from this study to the results from the natural history observational study (Pediatric Neuromuscular Clinical Research Network (PNCR), Finkel et al, 2014) are included in the Novartis Clinical Trial Results, as a historical control. These full results are available via this link: https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17933
Clinical trial NCT04212065: Long Acting Subcutaneous vs Short Acting Sublingual Buprenorphine in Pregnant and Lactating Women
Official title: Long Acting Subcutaneous Compared to Short Acting Sublingual Buprenorphine Administration in Pregnant and Lactating Women
Sponsor: Ohio State University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: closed due to new safety concerns of subcutaneous buprenorphine in pregnant patients
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-21
Primary completion date: 2020-09-01
Completion date: 2020-09-01
Plan to share individual participant data: NO
Clinical trial NCT03682393: Post-operative Corticosteroid Treatment After Mitral Valve Surgery
Official title: Does Post-operative Corticosteroid Treatment Prevent New-onset Atrial Fibrillation After Mitral Valve Surgery?
Acronym: MitralPOCS
Sponsor: Kuopio University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: the study never started
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-01
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Plan to share individual participant data: NO
IPD sharing description: IPD are not to be shared with other researchers.
Clinical trial NCT03782831: TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC
Official title: Transarterial Chemoembolization Plus Programmed Cell Death Protein-1 Antibody Versus Transarterial Chemoembolization Alone for Unresectable Hepatocellular Carcinoma
Sponsor: Sun Yat-sen University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No participants enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-12-11
Primary completion date: 2019-12-01
Completion date: 2020-06-01
Clinical trial NCT01546753: Walnut Oral Immunotherapy for Tree Nut Allergy
Official title: Walnut Oral Immunotherapy for Tree Nut Allergy
Acronym: WOIT
Sponsor: University of Arkansas (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 22.0 (ACTUAL)
Number of arms: 3.0
Start date: 2012-04-27
Primary completion date: 2015-07-02
Completion date: 2020-07-02
Limitations and caveats: Small sample size High screen failure rate High level of oropharyngeal symptoms Anxiety resulting in early termination Dosing fatigue with daily dosing Requirement for multiple food challenges in multi-tree nut assessment
Clinical trial NCT04996004: A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma
Official title: A Phase I/II Study of TTI-621 in Combination With Doxorubicin in Patients With Unresectable or Metastatic High-Grade Leiomyosarcoma
Acronym: TTI-621-03
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Pfizer decided to terminate the study for administrative reasons. The termination was neither due to safety concerns nor a request from the regulatory authorities.
Enrollment: 75.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-06-22
Primary completion date: 2023-12-07
Completion date: 2023-12-07
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04652414: Corticosteroids in Community Acquired Pneumonia
Official title: Corticosteroid Treatment for Community-Acquired Pneumonia to Improve Long-term Cognition: A Pilot Randomized Controlled Trial
Sponsor: Vanderbilt University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Limited enrollment due to the COVID-19 pandemic. Sponsor withdrew funding.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-01
Primary completion date: 2022-07-30
Completion date: 2022-07-30
Plan to share individual participant data: NO
Clinical trial NCT04839562: A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults
Official title: Solriamfetol for ADHD in Adults: A Double-Blind Placebo Controlled Pilot Study
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 66.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-06
Primary completion date: 2023-01-27
Completion date: 2023-01-27
Plan to share individual participant data: NO
Clinical trial NCT06177574: Study of Bictegravir/Emtricitavine/Tenofovir Alafenamide in HIV-1 Infected naïve Patients Using Test and Treat Stategy Rapid-initiation Model of Care: BIC-NOW Clinical Trial (BIC-NOW)
Official title: Study of Bictegravir/Emtricitavine/Tenofovir Alafenamide in HIV-1 Infected naïve Patients Using Test and Treat Stategy Rapid-initiation Model of Care: BIC-NOW Clinical Trial (BIC-NOW)
Acronym: BIC-NOW
Sponsor: University Hospital Virgen de las Nieves (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 208.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-10-27
Primary completion date: 2023-10-30
Completion date: 2023-10-30
Plan to share individual participant data: NO
Clinical trial NCT05338580: Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors
Official title: A Multi-center, Open-label Phase II Clinical Trial of TJ271 Injection in Combination With Pembrolizumab in Chinese Patients With Advanced Solid Tumors
Sponsor: TJ Biopharma Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Company Development strategy adjustment
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-12-31
Primary completion date: 2023-12-31
Completion date: 2023-12-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03720392: Fecal Microbiota Transplantation (FMT) in Recipients After Allogeneic Hematopoietic Cell Transplantation (HCT)
Official title: A Phase 2 Study of Fecal Microbiota Transplantation (FMT) in Recipients After Allogeneic Hematopoietic Cell Transplantation (HCT)
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Terminated due to sponsor decision
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-15
Primary completion date: 2020-05-28
Completion date: 2020-05-28
Plan to share individual participant data: NO
Clinical trial NCT03985878: A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995)
Official title: An Open-Label Safety, Tolerability, and Efficacy Study of Eteplirsen in Patients With Duchenne Muscular Dystrophy Who Have Completed Study 4658-102
Sponsor: Sarepta Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Participants were either transitioned to a post-trial access program or another Sarepta study, or they declined further treatment. There are no safety concerns with Eteplirsen.
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-06-26
Primary completion date: 2022-08-31
Completion date: 2022-08-31
Baseline population: Safety Set: all participants who received eteplirsen.
Limitations and caveats: In an effort to reduce clinical trial burden on participants while ensuring continued treatment if desired, pending commercial availability of eteplirsen, participants were either transitioned to a post-trial access program or another Sarepta study, or they declined further treatment.
Clinical trial NCT03255330: The Effect of Gabapentin Used as a Preemptive to the Emergence and Development Chronic Neuropathic Pain in Patients After Spinal Cord Trauma
Official title: The Effect of Gabapentin Used as a Preemptive to the Emergence and Development Chronic Neuropathic Pain in Patients After Spinal Cord Trauma
Acronym: GabaNeuBol
Sponsor: Masaryk University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: no participant enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-10-31
Primary completion date: 2020-02-29
Completion date: 2020-08-31
Clinical trial NCT04648241: Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older
Official title: A PHASE 3, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF A TICK-BORNE ENCEPHALITIS VACCINE IN HEALTHY JAPANESE PARTICIPANTS 1 YEAR OF AGE AND OLDER
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 165.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-18
Primary completion date: 2022-02-21
Completion date: 2022-02-21
Baseline population: Safety analysis population included all enrolled participants who received at least 1 dose of the investigational product.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03412890: LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Official title: LIBERTY EXTENSION: An International Phase 3 Open-Label, Single-Arm, Long-Term Efficacy and Safety Extension Study to Evaluate Relugolix Co-Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Sponsor: Myovant Sciences GmbH (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 477.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-10-19
Primary completion date: 2020-01-21
Completion date: 2021-01-13
Baseline population: Extension Safety Population: all enrolled participants who received any amount of open-label study drug in the open-label extension study.
Plan to share individual participant data: NO
Clinical trial NCT04918797: COVAXIN in a Pediatric Cohort
Official title: A Phase II/III, Open Label, Multicenter Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXIN®) in Healthy Volunteers Ages ≤18 to ≥ 2 Years.
Acronym: COVAXIN-Peds
Sponsor: Bharat Biotech International Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 525.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-05-26
Primary completion date: 2021-08-15
Completion date: 2022-01-25
Plan to share individual participant data: NO
Clinical trial NCT02536183: A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors
Official title: A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin (LTLD, ThermoDox®) and Magnetic Resonance-Guided High Intensity Focused Ultrasound (MR-HIFU) for Relapsed or Refractory Solid Tumors in Children, Adolescents, and Young Adults
Sponsor: Children's National Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: low accrual
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-10-31
Primary completion date: 2022-10-31
Completion date: 2022-10-31
Clinical trial NCT04772742: Eptinezumab in Adults With Migraine and Medication Overuse Headache
Official title: Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Eptinezumab for the Preventive Treatment of Migraine in Patients With a Dual Diagnosis of Migraine and Medication Overuse Headache
Acronym: Sunlight
Sponsor: H. Lundbeck A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 193.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-17
Primary completion date: 2022-05-23
Completion date: 2022-09-30
Plan to share individual participant data: YES
Clinical trial NCT03513445: Peri-Incisional Drug Injection in Lumbar Spine Surgery
Official title: Efficacy of Peri-Incisional Multimodal Drug Injection in Reducing Post-Operative Pain Following Lumbar Spine Surgery
Sponsor: University of Minnesota (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: No participants enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-06-01
Primary completion date: 2022-03-31
Completion date: 2022-09-30
Plan to share individual participant data: NO
Clinical trial NCT02933671: Suprainguinal Fascia Iliaca (SIFI) Block Improves Analgesia Following Total Hip Arthroplasty
Official title: Suprainguinal Fascia Iliaca (SIFI) Block Improves Analgesia Following Total Hip Arthroplasty
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Study halted prematurely and will not resume; participants are no longer being examined or receiving any intervention.
Enrollment: 11.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-08-01
Primary completion date: 2020-03-16
Completion date: 2020-03-17
Plan to share individual participant data: NO
IPD sharing description: Individual participant data will not be shared; patients will be deidentified and no personal information or medical records used.